Beacon Investment Advisory Services’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $421K | Sell |
1,290
-398
| -24% | -$130K | 0.02% | 180 |
|
|
2025
Q1 | $456K | Sell |
1,688
-2,033
| -55% | -$549K | 0.02% | 171 |
|
|
2024
Q4 | $876K | Sell |
3,721
-680
| -15% | -$160K | 0.04% | 138 |
|
|
2024
Q3 | $1.21M | Sell |
4,401
-235
| -5% | -$64.6K | 0.05% | 133 |
|
|
2024
Q2 | $1.13M | Sell |
4,636
-382
| -8% | -$92.8K | 0.05% | 131 |
|
|
2024
Q1 | $750K | Sell |
5,018
-437
| -8% | -$65.3K | 0.03% | 152 |
|
|
2023
Q4 | $1.04M | Sell |
5,455
-1,660
| -23% | -$318K | 0.05% | 141 |
|
|
2023
Q3 | $1.26M | Sell |
7,115
-3,041
| -30% | -$539K | 0.06% | 138 |
|
|
2023
Q2 | $1.93M | Sell |
10,156
-301
| -3% | -$57.2K | 0.09% | 128 |
|
|
2023
Q1 | $2.09M | Sell |
10,457
-183
| -2% | -$36.7K | 0.1% | 123 |
|
|
2022
Q4 | $2.53M | Sell |
10,640
-39
| -0.4% | -$9.27K | 0.13% | 114 |
|
|
2022
Q3 | $2.14M | Sell |
10,679
-227
| -2% | -$45.4K | 0.12% | 116 |
|
|
2022
Q2 | $1.59M | Sell |
10,906
-86
| -0.8% | -$12.5K | 0.08% | 130 |
|
|
2022
Q1 | $1.8M | Sell |
10,992
-21
| -0.2% | -$3.43K | 0.08% | 129 |
|
|
2021
Q4 | $1.87M | Buy |
11,013
+1,732
| +19% | +$294K | 0.07% | 137 |
|
|
2021
Q3 | $1.75M | Buy |
9,281
+346
| +4% | +$65.3K | 0.07% | 142 |
|
|
2021
Q2 | $1.52M | Buy |
8,935
+602
| +7% | +$102K | 0.06% | 145 |
|
|
2021
Q1 | $1.18M | Buy |
8,333
+3,803
| +84% | +$537K | 0.05% | 149 |
|
|
2020
Q4 | $589K | Buy |
+4,530
| New | +$589K | 0.03% | 174 |
|